MVA-BN Filo Publications

Capelle MAH, Babich L, van Deventer-Troost JPE, et al.

Stability and suitability for storage and distribution of Ad26.ZEBOV/MVA-BN®-Filo heterologous prime-boost Ebola vaccine

Eur J Pharm Biopharm. 2018 Aug;129:215-221. doi: 10.1016/j.ejpb.2018.06.001. Epub 2018 Jun 2
Callendret B, Vellinga J, Wunderlich K, et al.

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates

PLoS One. 2018 Feb 20;13(2):e0192312.
Winslow RL, Milligan ID, Voysey M, et al.

Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara–Vectored Ebola Vaccines at 1 Year

JAMA. 2017;317(10):1075-1077. doi:10.1001/jama.2016.20644
Milligan ID, Gibani MM, et al.

Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.

JAMA. 2016 Apr 19;315(15):1610-23. doi: 10.1001/jama.2016.4218.
Tapia MD, Sow SO, et al.

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.

Lancet Infect Dis. 2016 Jan;16(1):31-42. doi: 10.1016/S1473-3099(15)00362-X. Epub 2015 Nov 4.